azeliragon   Click here for help

GtoPdb Ligand ID: 8317

Synonyms: TTP488
Compound class: Synthetic organic
Comment: Azeliragon is an orally bioavailable small molecule that inhibits the receptor for advanced glycation endproducts (RAGE) [4-5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 14
Topological polar surface area 39
Molecular weight 531.27
XLogP 8.8
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES CCCCc1nc(cn1c1ccc(cc1)Oc1ccc(cc1)Cl)c1ccc(cc1)OCCCN(CC)CC
Isomeric SMILES CCCCc1nc(cn1c1ccc(cc1)Oc1ccc(cc1)Cl)c1ccc(cc1)OCCCN(CC)CC
InChI InChI=1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3
No information available.
Summary of Clinical Use Click here for help
Azeliragon is being assessed in Phase 2I clinical trial as a potential treatment for mild Alzheimer's disease (AD). The US FDA has granted azeliragon fast track designation, to expedite its route to approval, based on positive clinical outcomes from a Phase 2 trial [1].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Amyloid β (Aβ) uptake into the brain is dependent on RAGE [2]. Prolonged Aβ interaction with RAGE causes a chronic inflammation which is a crucial driver of amyloid plaque formation and chronic neuronal dysfunction. Thus RAGE is intimately linked to the pathogenesis of AD. Azeliragon antagonises the Aβ interaction with RAGE and is predicted to reduce Aβ accumulation in the brain, and has the potential to delay the formation of Aβ plaques.